People getting a subcutaneous implantable cardioverter-defibrillator (S-ICD) did fine skipping the defibrillation test after ...

The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus ...

Subcutaneous pembrolizumab has now been administered to the first patients in the UK following its nationwide rollout across ...

AstraZeneca’s SAPHNELO® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for the treatment of adult patients with systemic lupus ...

Argenx has filed for FDA approval of subcutaneous efgartigimod, keeping it on track to start selling the sibling of its existing intravenous generalized myasthenia gravis (gMG) treatment Vyvgart. In ...

Sarclisa (isatuximab) has been approved in the US since 2020, initially for relapsed/refractory multiple myeloma before ...

It’s looking like Roche may not receive an on-time FDA decision for the subcutaneous version of its cancer immunotherapy Tecentriq. The FDA was supposed to dole out a verdict on subcutaneous Tecentriq ...

AstraZeneca’s Saphnelo has been approved in the US for self‑administration as a once‑weekly autoinjector, the Saphnelo Pen, ...

Amlitelimab is safe and effective, with potentially progressive efficacy over time, for patients with moderate-to-severe atopic dermatitis.

Mim8 prophylaxis significantly reduced bleeding events in patients with or without inhibit ...

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...

Implementing subcutaneous opioid options in the emergency department significantly reduced reliance on intravenous administration.